`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`MEDTRONIC, INC., AND MEDTRONIC VASCULAR, INC.
`Petitioners,
`
`v.
`
`TELEFLEX INNOVATIONS S.A.R.L.
`Patent Owner.
`
`
`
`
`Case IPR2020-00132
`Patent RE 45,760
`
`
`
`
`PATENT OWNER’S UNOPPOSED MOTION TO FILE UNDER SEAL
`PURSUANT TO 37 C.F.R. §§ 42.14 AND 42.54
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1
`
`
`
`Pursuant to 37 C.F.R. §§ 42.14 and 42.54, Patent Owner respectfully
`
`submits this Patent Owner’s Unopposed Motion to File Under Seal, requesting that
`
`the following documents remain under seal: portions of Patent Owner’s
`
`Preliminary Response and certain exhibits filed with the Preliminary Response
`
`which are identified as Exhibits 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008,
`
`2009, 2010, 2011, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022,
`
`2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035,
`
`2036, 2037, 2038, 2040, 2041, 2043, 2045, 2058, and 2074. These documents are
`
`being filed concurrently with this motion.
`
`Patent Owner has conferred with the Petitioner, and the Petitioner does not
`
`oppose this motion to seal.
`
`Further, Patent Owner and Petitioner have conferred and agreed to the
`
`attached stipulated Joint Protective Order. A copy of the stipulated Joint Protective
`
`Order is attached as Appendix A. Patent Owner respectfully requests that the
`
`Board enter the attached stipulated Joint Protective order in the above captioned
`
`case.
`
`I.
`
`Good Cause
`
`For good cause, the Board may “issue an order to protect a party or person
`
`from disclosing confidential information.” 37 C.F.R. § 42.54. The rules “identify
`
`confidential information in a manner consistent with Federal Rule of Civil
`
`
`
`2
`
`
`
`Procedure 26(c)(1)(G), which provides for protective orders for trade secret or
`
`other confidential research, development, or commercial information.” Office
`
`Patent Trial Practice Guide, 77 Fed. Reg. 48756, 48760 (Aug. 14, 2012).
`
`Each of the seven categories of documents listed below meet this standard
`
`and for the reasons explained there is good cause for why those documents should
`
`remain under seal.
`
`A.
`
`Patent Owner’s Preliminary Response
`
`Patent Owner has filed an under seal and a public, redacted version of its
`
`Preliminary Response. Those portions of the under seal version of the Preliminary
`
`Response corresponding to the redacted portions of the public version of the
`
`Preliminary Response contain confidential research, development, and/or
`
`commercial information that should remain under seal.
`
`The redacted portions in the Introduction of the Preliminary Response and
`
`the second paragraph of section VIII.E.2.(a) and first redacted sentence of the third
`
`paragraph of that section, discuss business development information that
`
`Medtronic considers confidential.
`
`The remaining redacted portions of the Preliminary Response discuss
`
`revenue numbers for Patent Owner’s GuideLiner products and market share
`
`estimates. All of this information fits squarely within the kinds of information that
`
`the Trial Practice guide considers to be “confidential information,” such as
`
`
`
`3
`
`
`
`“confidential research, development, or commercial information.” 77 Fed. Reg.
`
`48756, 48760.
`
`There is good cause for keeping the redacted information contained in Patent
`
`Owner’s Preliminary Response under seal. Publicly revealing business
`
`development information, Patent Owner’s revenue numbers, and market share
`
`estimates could put Patent Owner (and possibly a competitor) at a competitive
`
`disadvantage in the marketplace. Additionally, Petitioners do not oppose this
`
`information remaining under seal.
`
`B.
`
`Exhibit 2001: Declaration of Howard Root Submitted in
`Connection with Patent Owner’s Preliminary Responses
`
`Exhibit 2001, filed under seal, is the Declaration of Howard Root Submitted
`
`
`
`in Connection with Patent Owner’s Preliminary Responses. Mr. Root’s declaration
`
`describes in detail the research and development of Patent Owner’s GuideLiner
`
`products, including component sourcing information, pricing information, and
`
`engineering and business decisions related to the development of the GuideLiner
`
`products. This information fits squarely within the kinds of information that the
`
`Trial Practice guide considers to be “confidential information,” such as
`
`“confidential research, development, or commercial information.” 77 Fed. Reg.
`
`48756, 48760.
`
`There is good cause for keeping Mr. Root’s declaration under seal. Publicly
`
`revealing the research and development activities of Patent Owner, along with
`4
`
`
`
`
`
`details regarding component sourcing, pricing, and engineering and business
`
`decisions related to the development of the GuideLiner products could put Patent
`
`Owner at a competitive disadvantage in the marketplace. Additionally, Petitioners
`
`do not oppose this information remaining under seal.
`
`C. Exhibits 2002-2011, 2013-2014, 2016-2038, 2040-2041, 2045:
`Development-Related Documents
`
`Exhibits 2002-2011, 2013-2014, 2016-2038, 2040-2041, 2045, filed under
`
`
`
`seal, are development documents related to the development of Patent Owner’s
`
`GuideLiner products. These development documents include laboratory notebook
`
`pages, market feasibility documents, technical design drawings, internal regulatory
`
`documents, an interrogatory response describing the development of the
`
`GuildeLiner products and invoices and purchasing documents, which among other
`
`things show confidential sourcing and pricing information. All of this information
`
`fits squarely within the kinds of information that the Trial Practice guide considers
`
`to be “confidential information,” such as “confidential research, development, or
`
`commercial information.” 77 Fed. Reg. 48756, 48760.
`
`There is good cause for keeping Exhibits 2002-2011, 2013-2014, 2016-
`
`2038, 2040-2041, 2045 under seal. Publicly revealing the development
`
`information related to the GuideLiner products described above could put Patent
`
`Owner at a competitive disadvantage in the marketplace. Additionally, Petitioners
`
`do not oppose this information remaining under seal.
`5
`
`
`
`
`
`D. Exhibit 2015: Howard Root Deposition Transcript
`
`Exhibit 2043, filed under seal, is the June 15, 2018 deposition transcript
`
`from the deposition of Howard Root in the case of QXMédical v. Vascular
`
`Solutions, LLC, 17-cv-01969-PJS-TNL (D. Minn.). The testimony was treated as
`
`confidential in the QXM Case. Much of the testimony provided by Mr. Root
`
`involves confidential information, including the design and development of Patent
`
`Owner’s GuideLiner products, marketing and business strategy, the discussion of
`
`confidential and attorney’s eyes only documents, and licensing information. This
`
`information fits squarely within the kinds of information that the Trial Practice
`
`guide considers to be “confidential information,” such as “confidential research,
`
`development, or commercial information.” 77 Fed. Reg. 48756, 48760.
`
`There is good cause for keeping Exhibit 2043 under seal. Publicly revealing
`
`the confidential information in Mr. Root’s deposition testimony could put Patent
`
`Owner at a competitive disadvantage in the marketplace. Additionally, Petitioners
`
`do not oppose this information remaining under seal.
`
`E.
`
`Exhibit 2043: Declaration of Amy Welch
`
`Exhibit 2043, filed under seal, is the Declaration of Amy Welch in Support
`
`of Plaintiffs’ Motion for Preliminary Injunction (“Welch Declaration”) that was
`
`filed under seal in the related district court case Vascular Solutions LLC v.
`
`Medtronic, Inc., 19-cv-01760-PJS-TNL (D. Minn.). Patent Owner has also filed
`
`
`
`6
`
`
`
`Exhibit 2044, which is the public, redacted version of the same Welch Declaration
`
`filed in the district court. Those portions of the under-seal version of the Welch
`
`Declaration corresponding to the redacted portions of the public version of the
`
`Welch Declaration contain confidential research, development, and/or commercial
`
`information that should remain under seal. For example, the redacted portions
`
`discuss confidential information, including financial information like worldwide
`
`sales, profit, and pricing information related to Patent Owner’s GuideLiner
`
`products, commercial strategy information related to the sale of GuideLiner
`
`products, market share estimates, information related to Patent Owner’s accounts
`
`and relationship with customers, licensing strategy, contract negotiations, and
`
`compensation for Patent Owner’s sales representatives. All of this information fits
`
`squarely within the kinds of information that the Trial Practice guide considers to
`
`be confidential commercial information. 77 Fed. Reg. 48756, 48760.
`
`There is good cause for keeping the redacted information contained in
`
`Exhibit 2043 under seal. Publicly revealing the commercially sensitive
`
`information noted above would put Patent Owner at a competitive disadvantage in
`
`the marketplace. Additionally, Petitioners do not oppose this information
`
`remaining under seal.
`
`
`
`7
`
`
`
`F.
`
`Exhibit 2058: Confidential Presentation
`
`Exhibit 2043, filed under seal, is a Vascular Solutions PowerPoint. This
`
`presentation reflects commercially sensitive discussions with a competitor, and
`
`includes commercially sensitive financial information regarding Patent Owner’s
`
`business. This information fits squarely within the kinds of information that the
`
`Trial Practice guide considers to be “confidential information,” such as
`
`“confidential . . . commercial information.” 77 Fed. Reg. 48756, 48760.
`
`There is good cause for keeping Exhibit 2043 under seal. Publicly revealing
`
`the commercially sensitive discussions and Patent Owner’s commercially sensitive
`
`financial information could put Patent Owner (and possibly a competitor) at a
`
`competitive disadvantage in the marketplace. Additionally, Petitioners do not
`
`oppose this information remaining under seal.
`
`G. Exhibit 2074: Declaration of Howard Root in Support of
`Plaintiffs’ Motion for Preliminary Injunction
`
`Exhibit 2074, filed under seal, is the Declaration of Howard Root in Support
`
`
`
`of Plaintiffs’ Motion for Preliminary Injunction. Mr. Root’s declaration describes
`
`in detail the research and development of Patent Owner’s GuideLiner products,
`
`including component sourcing information, pricing information, and engineering
`
`and business decisions related to the development of the GuideLiner products.
`
`This information fits squarely within the kinds of information that the Trial
`
`
`
`8
`
`
`
`Practice guide considers to be “confidential information,” such as “confidential
`
`research, development, or commercial information.” 77 Fed. Reg. 48756, 48760.
`
`There is good cause for keeping Mr. Root’s declaration under seal. Publicly
`
`revealing the research and development activities of Patent Owner, along with
`
`details regarding component sourcing, pricing, and engineering and business
`
`decisions related to the development of the GuideLiner products could put Patent
`
`Owner at a competitive disadvantage in the marketplace. Additionally, Petitioners
`
`do not oppose this information remaining under seal.
`
`II.
`
`Stipulated Joint Protective Order
`
`Attached hereto as Appendix A is a stipulated Joint Protective Order that has
`
`been agreed to by Petitioners and Patent Owner. Patent Owner respectfully
`
`requests that the Board enter this Joint Protective order in the above captioned
`
`case.
`
`Attached hereto as Appendix B is a redline comparing the stipulated Joint
`
`Protective Order to the Board’s Default Protective Order. The parties have
`
`modified the Default Protective Order, including to align it with the protective
`
`order entered in the district court case, Vascular Solutions LLC v. Medtronic, Inc.,
`
`19-cv-01760-PJS-TNL (D. Minn.), Dkt. 229. For example, the parties have
`
`modified the Default Protective Order: to make clear who may have access to
`
`confidential information, including the particular in-house counsel for each party;
`
`
`
`9
`
`
`
`how the parties should designate confidential testimony; to make clear that
`
`materials filed or produced in the above captioned matter should be filed in the
`
`litigation Vascular Solutions LLC et al. v. Medtronic Inc. et al., No. 19-cv-01760-
`
`PJS-TNL, and; to make clear that the parties agree to abide by this stipulated Joint
`
`Protective Order pending a decision by the Board.
`
`III. Certification of Conference
`
`Pursuant to 37 C.F.R. §§ 42.54(a), Patent Owner certifies that it has in good
`
`faith conferred with Petitioners’ counsel. Petitioners’ counsel does not oppose this
`
`motion to seal.
`
`Patent Owner also certifies that it has in good faith conferred with
`
`Petitioners’ counsel on the stipulated Joint Protective Order, and that both
`
`Petitioners and Patent Owner agree to abide by this Protective Order pending a
`
`decision by the Board on the motion for entry thereof.
`
`IV. Request for Conference Call with the Board
`
`Should the Board not be inclined to grant the present Unopposed Motion to
`
`File Under Seal, Patent Owner hereby requests a conference call with the Board to
`
`discuss any concerns prior to the Board issuing a decision on the Motion.
`
`V. Conclusion
`
`Patent Owner respectfully requests that the Board grant this Unopposed
`
`Motion to File Under Seal, and keep the following documents under seal: portions
`
`
`
`10
`
`
`
`of Patent Owner’s Preliminary Response, and Exhibits 2001, 2002, 2003, 2004,
`
`2005, 2006, 2007, 2008, 2009, 2010, 2011, 2013, 2014, 2015, 2016, 2017, 2018,
`
`2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031,
`
`2032, 2033, 2034, 2035, 2036, 2037, 2038, 2040, 2041, 2043, 2045, 2058, and
`
`2074.
`
`Patent Owner also requests that the Board enter the stipulated Joint
`
`Protective Order attached as Appendix A.
`
`
`Dated: March 10, 2020.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`/ J. Derek Vandenburgh /
`J. Derek Vandenburgh (Lead Counsel)
`Registration No. 32,179
`Carlson, Caspers, Vandenburgh
` & Lindquist, P.A.
`225 South Sixth Street, Suite 4200
`Minneapolis, MN 55402
`Telephone: (612) 436-9600
`Facsimile: (612) 436-9650
`Email:
`DVandenburgh@carlsoncaspers.com
`
`Lead Counsel for Patent Owner
`
`
`11
`
`
`
`CERTIFICATION OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e) and the agreement of the parties, the
`
`
`
`undersigned certifies that on March 10, 2020, a true and correct copy of the
`
`foregoing PATENT OWNER’S UNOPPOSED MOTION TO FILE UNDER SEAL
`
`PURSUANT TO 37 C.F.R. §§ 42.14 AND 42.54 was served via electronic mail
`
`upon the following:
`
`Cyrus A. Morton (Reg. No. 44,954)
`Sharon Roberg-Perez (Reg. No. 69,600)
`Christopher A. Pinahs (Reg. No. 76,375)
`Robins Kaplan LLP
`800 LaSalle Avenue, Suite 2800
`Minneapolis, MN 55401
`Phone: 349-8500
`Fax: 612-339-4181
`Email: Cmorton@robinskaplan.com
`Email: Sroberg-perez@robinskaplan.com
`Email: Cpinahs@robinskaplan.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`/J. Derek Vandenburgh/
`J. Derek Vandenburgh (Lead Counsel)
`
`
`
`12
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`MEDTRONIC, INC., AND MEDTRONIC VASCULAR, INC.
`Petitioners,
`
`v.
`
`TELEFLEX INNOVATIONS S.A.R.L.
`Patent Owner.
`
`
`
`
`Case IPR2020-00132
`Patent RE 45,760
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`JOINT PROTECTIVE ORDER
`
`
`
`Appendix A
`
`
`
`This Protective order governs the treatment and filing of confidential information,
`
`including documents and testimony.
`
`1. Confidential information shall be clearly marked “PROTECTIVE
`
`ORDER MATERIAL.”
`
`2. Access to confidential information is limited to the following individuals
`
`who have executed the acknowledgment appended to this order:
`
`(A) Party Representatives. Outside counsel for a party in the above-
`
`captioned proceeding.
`
`(B) Experts. Retained experts of a party in the proceeding who further
`
`certify in the Acknowledgement that they are not a competitor to any party,
`
`or a consultant for, or employed by, such a competitor with respect to the
`
`subject matter of the proceeding.
`
`(C) In-house counsel. Each party may designate up to 2 in-house counsel
`
`who are involved in this inter partes review, provided such in-house counsel
`
`has signed the Acknowledgement attached hereto as Exhibit A, their duties
`
`require them to assist outside counsel in this inter partes review, they do not
`
`have competitive decision making responsibilities or opportunity, and they
`
`are not involved in the prosecution or the supervision of the prosecution of
`
`any patents for any party. Petitioners designate: Chad Hanson and Matt
`
`Anderson. Patent Owner designates: Howard Cyr.
`
`Appendix A
`
`
`
`(D) Support Personnel. Administrative assistants, clerical staff, court
`
`reporters and other support personnel of the foregoing persons who are
`
`reasonably necessary to assist those persons in the proceeding shall not be
`
`required to sign an Acknowledgement, but shall be informed of the terms
`
`and requirements of the Protective Order by the person they are supporting
`
`who receives confidential information.
`
`(E) The Office. Employees and representatives of the United States Patent
`
`and Trademark Office who have a need for access to the confidential
`
`information shall have such access without the requirement to sign an
`
`Acknowledgement. Such employees and representatives shall include the
`
`Director, members of the Board and their clerical staff, other support
`
`personnel, court reporters, and other persons acting on behalf of the Office.
`
`
`
`3. Persons receiving confidential information shall use reasonable efforts to
`
`maintain the confidentiality of the information, including:
`
`(A) Maintaining such information in a secure location to which persons not
`
`authorized to receive the information shall not have access;
`
`(B) Otherwise using reasonable efforts to maintain the confidentiality of the
`
`Appendix A
`
`
`
`information, which efforts shall be no less rigorous than those the recipient
`
`uses to maintain the confidentiality of information not received from the
`
`disclosing party;
`
`(C) Ensuring that support personnel of the recipient who have access to the
`
`confidential information understand and abide by the obligation to maintain
`
`the confidentiality of information received that is designated as confidential;
`
`and
`
`(D) Limiting the copying of confidential information to a reasonable number
`
`of copies needed for conduct of the proceeding and maintaining a record of
`
`the locations of such copies.
`
`
`
`4. Persons receiving confidential information shall use the following
`
`procedures to maintain the confidentiality of the information:
`
`(A) Documents and Information Filed With the Board.
`
`(i) A party may file documents or information with the Board along with a
`
`Motion to Seal. The Motion to Seal should provide a non-confidential
`
`description of the nature of the confidential information that is under seal,
`
`and set forth the reasons why the information is confidential and should not
`
`be made available to the public. A party may challenge the confidentiality of
`
`the information by opposing the Motion to Seal. The submission shall be
`
`Appendix A
`
`
`
`treated as confidential and remain under seal, unless the Board determines
`
`that the documents or information do not to qualify for confidential
`
`treatment. The information shall remain under seal unless, upon motion of a
`
`party and after a hearing on the issue, or sua sponte, the Board determines
`
`that some or all of the information does not qualify for confidential
`
`treatment.
`
`(ii) Where confidentiality is alleged as to some but not all of the information
`
`submitted to the Board, the submitting party shall file confidential and
`
`non-confidential versions of its submission, together with a Motion to Seal
`
`the confidential version setting forth the reasons why the information
`
`redacted from the non-confidential version is confidential and should not be
`
`made available to the public. A party may challenge the confidentiality of
`
`the information by opposing the Motion to Seal. The non-confidential
`
`version of the submission shall clearly indicate the locations of information
`
`that has been redacted. The confidential version of the submission shall be
`
`filed under seal. The redacted information shall remain under seal unless,
`
`upon motion of a party and after a hearing on the issue, or sua sponte, the
`
`Board determines that some or all of the redacted information does not
`
`qualify for confidential treatment.
`
`(B) Documents and Information Exchanged Among the Parties. Documents
`
`Appendix A
`
`
`
`(including deposition transcripts) and other information designated as
`
`confidential that are disclosed to another party during discovery or other
`
`proceedings before the Board shall be clearly marked as “PROTECTIVE
`
`ORDER MATERIAL” and shall be produced in a manner that maintains its
`
`confidentiality.
`
`
`
`5. Confidential Testimony. Any person providing testimony in the
`
`proceeding may, on the record during the testimony, preliminarily designate the
`
`entirety of the person’s testimony and all transcriptions thereof as confidential,
`
`pending further review. Within ten days of the receipt of the transcript of the
`
`testimony, that person, or that person’s representative, shall advise the opposing
`
`party of those portions of the testimony to which a claim of confidentiality is to be
`
`maintained, and the reasons in support of that claim. Such portions shall be treated
`
`as confidential and maintained under seal in any filings to the Board unless, upon
`
`motion of a party and after a hearing on the issue, or sua sponte, the Board
`
`determines that some or all of the redacted information does not qualify for
`
`confidential treatment.
`
`
`
`6. Within 60 days after the final disposition of this action, including the
`
`Appendix A
`
`
`
`exhaustion of all appeals and motions, each party receiving confidential
`
`information must certify the destruction of, all copies of the confidential
`
`information to the producing party.
`
`
`
`7. Each party will produce all materials produced or filed during the course
`
`of the above-captioned proceeding in the litigation captioned as Vascular Solutions
`
`LLC et al. v. Medtronic Inc. et al., No. 19-cv-01760-PJS-TNL with litigation Bates
`
`stamps within 14 days after filing or serving such information in the above-
`
`captioned proceeding.
`
`
`
`8. The Parties agree to abide by this Protective Order pending a decision by
`
`the Board on the Parties’ motion for entry thereof.
`
`
`
`9. Standard Acknowledgement of Protective Order. The following form will
`
`be used to acknowledge a protective order and gain access to information covered
`
`by the protective order:
`
`
`
`
`
`
`
`Appendix A
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`MEDTRONIC, INC., AND MEDTRONIC VASCULAR, INC.
`Petitioners,
`
`v.
`
`TELEFLEX INNOVATIONS S.A.R.L.
`Patent Owner.
`
`
`
`
`Case Nos. IPR2020-00126, -00127, -00128,
`-00129, -00130, -00131, -00132, -00133,
`-00134, -00135, -00136, -00137, -00138
`
`
`
`
`
`
`Standard Acknowledgment for Access to Protective Order Material
`
`
`
`
`
`I __________________________________________, affirm that I have
`read the Protective Order; that I will abide by its terms; that I will use the
`confidential information only in connection with this proceeding and for no other
`purpose; that I will only allow access to support staff who are reasonably necessary
`to assist me in this proceeding; that prior to any disclosure to such support staff I
`informed or will inform them of the requirements of the Protective Order; that I am
`personally responsible for the requirements of the terms of the Protective Order
`and I agree to submit to the jurisdiction of the Office and the United States District
`Court for the Eastern District of Virginia for purposes of enforcing the terms of the
`Protective Order and providing remedies for its breach.
`
`
`_______________________________________ Date: ______________
`[Signature]
`
`
`
`Appendix A
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`MEDTRONIC, INC., AND MEDTRONIC VASCULAR, INC.
`Petitioners,
`
`v.
`
`TELEFLEX INNOVATIONS S.A.R.L.
`Patent Owner.
`
`
`
`
`Case IPR2020-00132
`Patent RE 45,760
`
`
`
`
`
`
`
`
`
`JOINT PROTECTIVE ORDER
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Appendix B
`
`
`
`This protective order governs the treatment and filing of confidential information,
`
`including documents and testimony.
`
`1. Confidential information shall be clearly marked “PROTECTIVE ORDER
`
`MATERIAL.”
`
`
`
`2. Access to confidential information is limited to the following individuals who
`
`have executed the acknowledgment appended to this order:
`
`(A) Parties. Persons who are owners of a patent involved in the proceeding and
`
`other persons who are named parties to the proceeding.
`
`(AB) Party Representatives. Representatives of recordOutside counsel for a party
`
`in the above-captioned proceeding.
`
`(BC) Experts. Retained experts of a party in the proceeding who further certify in
`
`the Acknowledgement that they are not a competitor to any party, or a consultant
`
`for, or employed by, such a competitor with respect to the subject matter of the
`
`proceeding.
`
`(CD) In-house counsel. Each party may designate up to 2 in-house counsel who are
`
`involved in this inter partes review, provided such in-house counsel has signed the
`
`Acknowledgement attached hereto as Exhibit A, their duties require them to assist
`
`outside counsel in this inter partes review, they do not have competitive decision
`
`making responsibilities or opportunity, and they are not involved in the prosecution
`
`Appendix B
`
`
`
`or the supervision of the prosecution of any patents for any party. Petitioners
`
`designate: Chad Hanson and Matt Anderson. Patent Owner designates: Howard
`
`Cyr. In-house counsel of a party.
`
`(DE) Support Personnel. Administrative assistants, clerical staff, court reporters
`
`and other support personnel of the foregoing persons who are reasonably necessary
`
`to assist those persons in the proceeding shall not be required to sign an
`
`Acknowledgement, but shall be informed of the terms and requirements of the
`
`Protective Order by the person they are supporting who receives confidential
`
`information.
`
`(EF) The Office. Employees and representatives of the United States Patent and
`
`Trademark Office who have a need for access to the confidential information shall
`
`have such access without the requirement to sign an Acknowledgement. Such
`
`employees and representatives shall include the Director, members of the Board
`
`and their clerical staff, other support personnel, court reporters, and other persons
`
`acting on behalf of the Office.
`
`
`
`3. Employees (e.g., corporate officers), consultants, or other persons performing
`
`work for a party, other than those persons identified above in (d)(2)(A)–(E), shall
`
`be extended access to confidential information only upon agreement of the parties
`
`or by order of the Board upon a motion brought by the party seeking to disclose
`
`Appendix B
`
`
`
`confidential information to that person and after signing the Acknowledgment. The
`
`party opposing disclosure to that person shall have the burden of proving that such
`
`person should be restricted from access to confidential information.
`
`
`
`34. Persons receiving confidential information shall use reasonable efforts to
`
`maintain the confidentiality of the information, including:
`
`(A) Maintaining such information in a secure location to which persons not
`
`authorized to receive the information shall not have access;
`
`(B) Otherwise using reasonable efforts to maintain the confidentiality of the
`
`information, which efforts shall be no less rigorous than those the recipient uses to
`
`maintain the confidentiality of information not received from the disclosing party;
`
`(C) Ensuring that support personnel of the recipient who have access to the
`
`confidential information understand and abide by the obligation to maintain the
`
`confidentiality of information received that is designated as confidential; and
`
`(D) Limiting the copying of confidential information to a reasonable number of
`
`copies needed for conduct of the proceeding and maintaining a record of the
`
`locations of such copies.
`
`
`
`45. Persons receiving confidential information shall use the following procedures
`
`to maintain the confidentiality of the information:
`
`Appendix B
`
`
`
`(A) Documents and Information Filed With the Board.
`
`(i) A party may file documents or information with the Board along with a Motion
`
`to Seal. The Motion to Seal should provide a non-confidential description of the
`
`nature of the confidential information that is under seal, and set forth the reasons
`
`why the information is confidential and should not be made available to the
`
`public. A party may challenge the confidentiality of the information by opposing
`
`the Motion to Seal. The submission shall be treated as confidential and remain
`
`under seal, unless the Board determines that the documents or information do not
`
`to qualify for confidential treatment. The information The documents or
`
`information shall remain under seal unless, upon motion of a party and after a
`
`hearing on the issue, or sua sponte, the Board determines that some or all of the
`
`information it does not qualify for confidential treatment.
`
`(ii) Where confidentiality is alleged as to some but not all of the information
`
`submitted to the Board, the submitting party shall file confidential and
`
`non-confidential versions of its submission, together with a Motion to Seal the
`
`confidential version setting forth the reasons why the information redacted from
`
`the non-confidential version is confidential and should not be made available to
`
`the public. A party may challenge the confidentiality of the information by
`
`opposing the Motion to Seal. The non-confidential version of the submission
`
`shall clearly indicate the locations of information that has been redacted. The
`
`Appendix B
`
`
`
`confidential version of the submission shall be filed under seal. The redacted
`
`information shall remain under seal unless, upon motion of a party and after a
`
`hearing on the issue, or sua sponte, the Board determines that some or all
`
`of the redacted information does not qualify for confidential treatment.
`
`(B) Documents and Information Exchanged Among the Parties. Documents
`
`(including deposition transcripts) and other information designated as confidential
`
`that are disclosed to another party during discovery or other proceedings before
`
`the Board shall be clearly marked as “PROTECTIVE ORDER MATERIAL” and
`
`shall be produced in a manner that maintains its confidentiality.
`
`
`
`5. Confidential Testimony. Any person providing testimony in the proceeding may,
`
`on the record during the testimony, preliminarily designate the entirety of the
`
`person’s testimony and all transcriptions thereof as confidential, pending further
`
`review. Within ten days of the receipt of the transcript of the testimony, that
`
`person, or that person’s representative, shall advise the opposing party of those
`
`portions of the testimony to which a claim of confidentiality is to be maintained,
`
`and the reasons in support of that claim. Such portions shall be treated as
`
`confidential and maintained under seal in any filings to the Board unless, upon
`
`motion of a party and after a hearing on the issue, or sua sponte, the Board
`
`Appendix B
`
`
`
`determines that some or all of the redacted information does not qualify for
`
`confidential treatment.
`
`
`
`6. Within 60 days after the final disposition of this action, including the
`
`exhaustion of all appeals and motions, each party receiving confidential
`
`information must return, or certify the destruction of, all copies of the confidential
`
`information to the producing party.
`
`
`
`7. Each party will produce all materials produced or filed during the course of the
`
`above-captioned proceeding in the litigation captioned as Vascular Solutions LLC
`
`et al. v. Medtronic Inc. et al., No. 19-cv-01760-PJS-TNL with litigation Bates
`
`stamps within 14 days after filing or serving such information in the above-
`
`captioned proceeding.
`
`
`
`8. The Parties agree to abide by this Protective Order pending a decision